LG Chem begins Phase 2 trials for infant hexavalent vaccine
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.08.14 05:11:34
가나다라
0
Phase 1 clinical results demonstrated the immunogenicity and safety of the vaccine, similar to conventional products
Will commence the Phase 2 trial for the hexavalent 'acellular Pertussis (aP)' vaccine, LR20062
Intends to commercialize the first domestically produced combination therapy…expected to stabilize the essential vaccine distribution
▲LG Chem
LG Chem prepares to commence the Phase 2 clinical trial for its hexavalent vaccine LR20062. The company aims to domestically produce infant combination vaccines in South Korea. Since South Korea has so far relied entirely on imported combination vaccines, the company plans to provide a stable supply network to meet mid- to-long term demand for immunization.
On August 13th, LG Chem announced it will conduct the Phase 2 trials for the hexavalent 'acellular Pertussis (aP)' vaccine, 'LR20062' overseas and prepare to enroll study participants.
The successful completion of the Phase 1 trial and entry into the Phase 2 stage indicate progress towards commercializing the first dom
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)